Draft Guidance for M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms

The guidelines provide recommendations for conducting BE studies during development and post-approval phases for orally administered IR solid oral dosage forms designed to deliver drugs to the systemic circulation, such as tablets, capsules, and granules/powders for oral suspension.

Download draft guidance here.